Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ursodeoxycholic acid + total glucosides of paeony
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of ursodeoxycholic acid (UDCA) and total glucosides of paeony (TGP). UDCA is a naturally occurring bile acid that constitutes a minor fraction of the human bile acid pool and is used to treat liver diseases by replacing more toxic bile acids. TGP is an active compound extracted from the dried roots of Paeonia lactiflora Pall with immunomodulatory and anti-inflammatory properties. This combination is being investigated for the treatment of primary biliary cholangitis (PBC) with autoimmune hepatitis (AIH) features.
02
Targets
ABCB11 (Bile salt export pump)FXR (Farnesoid x-activated receptor)
Beyond the preview
Go deeper on ursodeoxycholic acid + total glucosides of paeony.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ursodeoxycholic acid + total glucosides of paeony.